Young Oncologists Corner

Oncology Fellowships

Invest in your future and the future of cancer care. Learn more about our Oncology Fellowship Programme.

Jobs in Oncology

The latest oncology jobs can be found here, including information on how to post a job.

Awards

ESMO Full, Honorary and Emeritus members: we are now accepting nominations for the 2015 ESMO Awards

Global Curriculum in Medical Oncology

ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology is now available in Serbian

Clinical Trials Workshops

ESMO fosters the advancement of cancer research by supporting clinical trials workshops to inspire young oncologists from different disciplines across the globe to become the next generation of active researchers.

ESMO Examination

ESMO members: are you planning on taking the ESMO examination this year? Register now and benefit from our early registration discount

Recertification & CME

If you’ve already sat the ESMO exam, then take a look at our CME opportunities.

Women 4 Oncology

Discover the results of the ESMO Survey on the challenges faced by female oncologists

Patient Guides

Most ESMO Cancer Guides for Patients are now available in Greek. Download your copy now!

Personalised Medicine Explained

Video interviews and articles designed to help patients, policy makers and other non-medical professionals better understand the principles of personalised cancer medicine

Getting the Most out of Your Oncologist

Now available in Greek, our Guide for Patients with Advanced Cancer is designed for patients, their family members and oncologists.

Designated Centres of Integrated Oncology and Palliative Care

The ESMO Designated Centres of Integrated Oncology and Palliative Care accreditation programme recognises cancer centres which provide comprehensive services in supportive and palliative care as part of their routine care.

Surveys

Read the reports from the ESMO/EAPC opioid survey and the oncologist/patient communication survey.

A key role of dysregulated chromatin remodeling

Exome sequencing of 32 intrahepatic cholangiocarcinomas has revealed recurrent inactivating mutations in several genes involved in chromatin remodelling that were previously unknown in this type of cancer. The study also identified frequent mutations at previously reported hotspots in the genes encoding metabolic enzymes. The findings are published as a research letter in the Nature Genetics on 3 November, 2013 by Yuchen Jiao of the Ludwig Center, Johns Hopkins University, Baltimore, USA and international study colleagues. The corresponding authors are Aldo Scarpa, Kenneth Kinzler, Nickolas Papadopoulos and Laura Wood.

Through exomic sequencing of intrahepatic cholangiocarcinomas, the study team discovered frequent inactivating mutations in multiple chromatin-remodeling genes, including BAP1, ARID1A and PBRM1). Mutation in one of these genes occurred in almost half of the carcinomas sequenced.

Dysfunctional metabolism has also been implicated in this cancer type with the identification of frequent mutations in IDH1 and IDH2, which encode isocitrate dehydrogenase. In contrast, TP53 was the most frequently altered gene in a series of nine gallbladder carcinomas. The authors concluded that these discoveries highlight the key role of dysregulated chromatin remodeling in intrahepatic cholangiocarcinomas.

As competing financial interests, the authors reported under agreements between Johns Hopkins University, Genzyme, Myriad Genetics, Exact Sciences, Inostics, Qiagen, Invitrogen and Personal Genome Diagnostics, Victor Velculescu, Nickolas Papadopoulos, Bert Vogelstein, Kenneth Kinzler and Ralph Hruban are entitled to a share of the royalties received by Johns Hopkins University on sales of products related to genes and technologies described in this manuscript. Victor Velculescu, Nickolas Papadopoulos, Bert Vogelstein and Kenneth Kinzler are cofounders of Inostics and Personal Genome Diagnostics, are members of their scientific advisory boards and own Inostics and Personal Genome Diagnostics stock, which is subject to certain restrictions under Johns Hopkins University policy. Laura Wood is a paid consultant for Personal Genome Diagnostics. The contribution of Donald Lucas to this manuscript represents his own views and not the official policy of the USA Navy, USA Department of Defense or USA government.